DK1155692T3 - Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel - Google Patents

Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel

Info

Publication number
DK1155692T3
DK1155692T3 DK01110509T DK01110509T DK1155692T3 DK 1155692 T3 DK1155692 T3 DK 1155692T3 DK 01110509 T DK01110509 T DK 01110509T DK 01110509 T DK01110509 T DK 01110509T DK 1155692 T3 DK1155692 T3 DK 1155692T3
Authority
DK
Denmark
Prior art keywords
drug
treatment
solid tumors
manufacture
well
Prior art date
Application number
DK01110509T
Other languages
Danish (da)
English (en)
Inventor
Marco Falciani
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1155692(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Application granted granted Critical
Publication of DK1155692T3 publication Critical patent/DK1155692T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01110509T 2000-05-18 2001-04-27 Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel DK1155692T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (1)

Publication Number Publication Date
DK1155692T3 true DK1155692T3 (da) 2004-08-09

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01110509T DK1155692T3 (da) 2000-05-18 2001-04-27 Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel

Country Status (22)

Country Link
US (1) US6652884B2 (enExample)
EP (1) EP1155692B1 (enExample)
JP (1) JP2001354559A (enExample)
KR (2) KR20010105248A (enExample)
CN (1) CN1198609C (enExample)
AT (1) ATE267594T1 (enExample)
AU (1) AU781517B2 (enExample)
BR (1) BR0102040A (enExample)
CA (1) CA2345482A1 (enExample)
DE (1) DE60103453T2 (enExample)
DK (1) DK1155692T3 (enExample)
ES (1) ES2221874T3 (enExample)
HU (1) HU229909B1 (enExample)
IL (1) IL142674A0 (enExample)
IT (1) ITMI20001107A1 (enExample)
MX (1) MXPA01004980A (enExample)
NO (1) NO330511B1 (enExample)
NZ (1) NZ511201A (enExample)
PT (1) PT1155692E (enExample)
RU (1) RU2270003C2 (enExample)
TR (1) TR200101353A3 (enExample)
ZA (1) ZA200103755B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) * 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2007069272A2 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
LT2481409T (lt) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
DK2155188T3 (da) 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
AU2010236382B2 (en) 2009-04-15 2016-01-14 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
AU2014228386B2 (en) * 2013-03-13 2018-11-29 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
CN109906088A (zh) 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用
TWI660728B (zh) 2018-02-09 2019-06-01 國立交通大學 胺基喹唑啉衍生物及其醫藥組合物與用途
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
CN120919082A (zh) * 2025-10-16 2025-11-11 天津医科大学总医院 一种负载蛋白药物的GelMA微球、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
EP1100494A1 (en) 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin

Also Published As

Publication number Publication date
JP2001354559A (ja) 2001-12-25
EP1155692A1 (en) 2001-11-21
ZA200103755B (en) 2001-11-15
PT1155692E (pt) 2004-09-30
ES2221874T3 (es) 2005-01-16
DE60103453T2 (de) 2005-06-23
NO330511B1 (no) 2011-05-09
CN1324613A (zh) 2001-12-05
EP1155692B1 (en) 2004-05-26
DE60103453D1 (de) 2004-07-01
CA2345482A1 (en) 2001-11-18
NO20012409L (no) 2001-11-19
KR20010105248A (ko) 2001-11-28
ATE267594T1 (de) 2004-06-15
CN1198609C (zh) 2005-04-27
ITMI20001107A1 (it) 2001-11-18
US6652884B2 (en) 2003-11-25
TR200101353A2 (tr) 2001-12-21
HU229909B1 (en) 2014-12-29
ITMI20001107A0 (it) 2000-05-18
NO20012409D0 (no) 2001-05-16
BR0102040A (pt) 2002-03-19
AU781517B2 (en) 2005-05-26
HUP0102039A3 (en) 2002-12-28
RU2270003C2 (ru) 2006-02-20
HK1040368A1 (en) 2002-06-07
MXPA01004980A (es) 2002-08-06
HU0102039D0 (en) 2001-07-30
IL142674A0 (en) 2002-03-10
AU3876501A (en) 2001-11-22
KR20080091747A (ko) 2008-10-14
NZ511201A (en) 2002-11-26
US20010046961A1 (en) 2001-11-29
HUP0102039A2 (hu) 2002-05-29
TR200101353A3 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
DK1155692T3 (da) Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
CY1113312T1 (el) Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
DK1239829T3 (da) Indretninger til indgivelse af medikamenter med antiprogestinegenskaber
NO20034931L (no) Substituerte 2-pyridin-cykloheksan-1,4-diaminderivater
DK1439829T3 (da) Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof
NO20031018D0 (no) Oksymorfonpreparater med kontrollert frigivelse
DK1443955T3 (da) PDGF-BB til behandling af Parkinsons sygdom
DK1265889T3 (da) Lægemidler imod virussygdomme
DE69907977D1 (de) Pyrrolobenzodiazepine
NO20093060L (no) Spirosykliske sykloheksanderivater
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1242060T3 (da) Behandling af metastatisk sygdom
DK1268472T3 (da) 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
DK1214061T3 (da) Anvendelse af docetaxel til behandling af hepatocellulært carcinom
DE60112960D1 (de) Kondensierte pyridoindolderivate
NO20014752D0 (no) Taksanpreparater med forbedret opplöselighet
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
HRP20080447T3 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
BR0314838A (pt) Sistema de liberação controlada, e, processo para preparar comprimidos de liberação controlada de temozolomida
EE200200605A (et) Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks
DK1615668T3 (da) Et lægemiddel til to-trins perioperativ behandling af faste tumorer med radioimmunoterapi
DK1390364T3 (da) Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression